A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006
In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhalerSource: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
In vitro testing of two budesonide dry powder inhalers at different flow ratesSource: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests Year: 2012
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Impact of critical handling errors on delivered budesonide/formoterol dose in dry powder inhalers – An in vitro study Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo Source: Eur Respir J 2001; 18: Suppl. 33, 123s Year: 2001
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012